Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12612000184875
Ethics application status
Approved
Date submitted
6/02/2012
Date registered
10/02/2012
Date last updated
10/02/2012
Type of registration
Retrospectively registered

Titles & IDs
Public title
Efficacy and Safety Study of dihydroartemisinin-piperaquine (DP) and atovaquone-proguanil (AP) for the Treatment of Uncomplicated Plasmodium falciparum (P.f) malaria and Chloroquine (CQ) for the treatment of Plasmodium vivax (P.v) Malaria in Cambodia 2008
Scientific title
Efficacy and Safety Study of dihydroartemisinin-piperaquine (DP) and atovaquone-proguanil (AP) for the Treatment of Uncomplicated Plasmodium falciparum (P.f) malaria and Chloroquine (CQ) for the treatment of Plasmodium vivax (P.v) Malaria in Cambodia 2008
Secondary ID [1] 279890 0
Nil
Universal Trial Number (UTN)
U1111-1227-9908
Trial acronym
TESCAM08
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Malaria 285790 0
Condition category
Condition code
Infection 285967 285967 0 0
Studies of infection and infectious agents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Study drugs were dihydroartemisinin-piperaquine (DP), atovaquone-proguanil (AP) and Chloroquine (CQ). One group was treated with DP over 3 days , another group was treated with AP over 3 days for P.f cases. In a separate group of patients with P. vivax malaria, CQ alone was used for treatment.

DP (oral tablet) with a dose of 4mg/kg for D and 20mg/kg for P daily for 3 days

AP (oral tablet) with a dose of A at 15mg/kg and P at 6mg/kg daily for 3 days

CQ (oral tablets) at 10mg/kg on Day 1, 10mg/kg on Day 2and 5 mg/kg on Day3.
Intervention code [1] 284212 0
Treatment: Drugs
Comparator / control treatment
No control and comparator group. This was a single group trial. In falciparum infected patients, DP was tested in Pailin. DP was tested first and when it was finished AP was tested for another group of patients in Veal Veng site. In a separate group of vivax infected patients, CQ was tested in Pailin.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 286466 0
42-day cure rate or ACPR (adequate clinical and parasitological response for falciparum cases and 28-day for vivax.

42-day PCR-corrected ACPR (PCR: polymerase chain reaction, a molecular tool/test to differentiate if the failure is a true resistance or reinfection) for falciparum cases only
Timepoint [1] 286466 0
at the end of 42-day follow up for falciparum cases and end of 28 days for vivax cases.
Secondary outcome [1] 295935 0
Reported signs and symptoms of adverse effects during the time of drug administration were collected in the case record form. The patients may experience the following adverse effect.

1 Dizziness
2 Headache
3 Vestige
4 Nausea
5 Vomiting
6 Diarrhea
7 Abdomen pain 8 Dark Urine
Timepoint [1] 295935 0
first 3 days of drug administration

Eligibility
Key inclusion criteria
-Above 2years old (all age groups);
-Mono Infection with P. falciparum or P. vivax;
-Parasitaemia, 1000–200 000 asexual forms per microlitre ;
-Axillary temperature greater than 37.5 degree C
-Ability to swallow oral medication;
-Ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule;
-Informed consent from the patient or from a parent or guardian in case of children.
Minimum age
2 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
-Presence of general danger signs among children <5 years old or other signs of severe and complicated falciparum malaria according to current WHO definitions;
-Mixed species;
-Presence of febrile conditions due to diseases other than malaria (measles, acute lower tract respiratory infection, severe diarrhea with dehydration, etc.),
-Known hypersensitivity or allergy to artesunate or mefloquine
-Known psychiatric disorders, e.g. depression or epilepsy
-Anti arrhythmic or others drugs which are known to influence cardiac function

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
This is a modified single group study where participants received the same drug per site per specie infection. Patients were enrolled in a sequential manner as they come for consultation at the study site and satisfy the inclusion criteria.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Nil
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 4
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
22/07/2008
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
240
Accrual to date
Final
Recruitment outside Australia
Country [1] 4109 0
Cambodia
State/province [1] 4109 0
Pailin
Country [2] 4110 0
Cambodia
State/province [2] 4110 0
Pursat

Funding & Sponsors
Funding source category [1] 284658 0
Other
Name [1] 284658 0
WHO
Country [1] 284658 0
Philippines
Primary sponsor type
Other
Name
Global Fund For Malaria
Address
# 372 Monivong Blvd, Phnom Penh, Cambodia
Country
Cambodia
Secondary sponsor category [1] 283564 0
Government body
Name [1] 283564 0
National Centre for Parasitology, Entomology and Malaria Control
Address [1] 283564 0
#372 Monivong Blvd, Phnom Penh Cambodia
Country [1] 283564 0
Cambodia
Other collaborator category [1] 260520 0
Other
Name [1] 260520 0
Institude Paster du Cambodge
Address [1] 260520 0
Monivong Blvd, Phnom Penh Cambodia
Country [1] 260520 0
Cambodia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 286655 0
National Ethics Comittee for Health Research
Ethics committee address [1] 286655 0
Ethics committee country [1] 286655 0
Cambodia
Date submitted for ethics approval [1] 286655 0
11/03/2008
Approval date [1] 286655 0
11/04/2008
Ethics approval number [1] 286655 0
041NECHR

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 33742 0
Address 33742 0
Country 33742 0
Phone 33742 0
Fax 33742 0
Email 33742 0
Contact person for public queries
Name 16989 0
Dr. Char Meng Chuor
Address 16989 0
National Centre for Parasitology, Entomology and Malaria Control
#372 Monivong Blvd, Phnom Penh
Country 16989 0
Cambodia
Phone 16989 0
855 12 841168
Fax 16989 0
Email 16989 0
mengchuor@gmail.com
Contact person for scientific queries
Name 7917 0
Steven Bijorge
Address 7917 0
World Health Organization Office to representative of Cambodia
#177-179 Corner Streets Pasteur (51) and 254, Sangkat Chak Tomouk, Khan Daun Penh, Phnom Penh
Country 7917 0
Cambodia
Phone 7917 0
(855) 12666431
Fax 7917 0
Email 7917 0
bjorges@wpro.who.int

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.